Focused Antibody and DNA Production for CVV Investigation
Closed Solicitation Posted
- Solicitation number
- 75D30124Q78087
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- Place of performance
- Atlanta, Georgia, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) Influenza Division is seeking to procure synthetic genes, gene modifications, and other genetic products to support the development and characterization of Candidate Vaccine Viruses (CVVs) for influenza pandemic preparedness. The requirement is driven by the constant genetic changes in circulating and novel influenza viruses, which are unpredictable and cannot be identified until the viruses are isolated. The contract is a firm-fixed price arrangement, and the solicitation includes a Statement of Work detailing the required tasks, which include recombinant antibody production, gene synthesis and cloning, mutagenesis, plasmid scale-up, glycerol stock creation, and circular RNA synthesis. Quotations are due by August 27, 2024, and the Government intends to award a contract as a result of this solicitation.
This solicitation is not set-aside, and there are no known incumbent contractors. The anticipated award value is not provided. The place of performance is Atlanta, GA, USA, and the NAICS code is 325414 - Biological Product (except Diagnostic) Manufacturing, with a PSC code of 6550-P - In Vitro Diagnostic Substances, Reagents, Test Kits And Sets.
Notice text
2 versions
Update #2 · Latest ·
This amendment is re-opening the solicitation to allow for further competition. All quotes shall be due by 3:00 PM EDT on Tuesday September 10, 2024. Additional questions, if any, are due by 3:00 PM EDT on Thursday September 5, 2024.
CDC Influenza Division (ID) is responsible for the development of Candidate Vaccine Viruses (CVV) based on circulating and novel influenza strains. CVVs are reassortant viruses which are used as the starting materials for seasonal and pandemic vaccines. To facilitate the development of CVVs, the CDC uses synthetic genes to transcribe viral genes to produce CVVs. Interactions between viruses and host proteins can elucidate molecular properties of viruses not readily apparent by other means. Expressing proteins from engineered plasmids is the foundation of most downstream assays utilized in this regard.
Accordingly, the Influenza Division requires synthetic genes, produced by de novo synthesis or modifications of existing templates through mutagenesis, and other genetic products to be developed routinely based on the constant changes in the genetic makeup of the circulating and novel viruses. These changes are unpredictable and cannot be identified until the viruses are isolated from patients or infected animals.
Update #1 ·
CDC Influenza Division (ID) is responsible for the development of Candidate Vaccine Viruses (CVV) based on circulating and novel influenza strains. CVVs are reassortant viruses which are used as the starting materials for seasonal and pandemic vaccines. To facilitate the development of CVVs, the CDC uses synthetic genes to transcribe viral genes to produce CVVs. Interactions between viruses and host proteins can elucidate molecular properties of viruses not readily apparent by other means. Expressing proteins from engineered plasmids is the foundation of most downstream assays utilized in this regard.
Accordingly, the Influenza Division requires synthetic genes, produced by de novo synthesis or modifications of existing templates through mutagenesis, and other genetic products to be developed routinely based on the constant changes in the genetic makeup of the circulating and novel viruses. These changes are unpredictable and cannot be identified until the viruses are isolated from patients or infected animals.
Files
| File | Type | Posted |
|---|---|---|
| 75D30124Q78087 Amendment 2.pdf | ||
| Amendment_00001_RFQ_75D30124Q78087.pdf | ||
| A19_75D30124Q78087.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity